Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity.

Emma C Thomson ORCID logo; Laura ERosen; James GShepherd; RobertoSpreafico; Anada Silva Filipe; Jason AWojcechowskyj; ChrisDavis; LucaPiccoli; David JPascall; JoshDillen; +58 more... SpyrosLytras; NadineCzudnochowski; RajivShah; MarcelMeury; NatashaJesudason; AnnaDe Marco; KathyLi; JessicaBassi; AineO'Toole; DoraPinto; Rachel MColquhoun; KatjaCulap; BenJackson; FabriziaZatta; AndrewRambaut; StefanoJaconi; Vattipally BSreenu; JayNix; IvyZhang; Ruth FJarrett; William GGlass; MartinaBeltramello; KyriakiNomikou; MatteoPizzuto; LilyTong; ElisabettaCameroni; Tristan ICroll; NatashaJohnson; JuliaDi Iulio; ArthurWickenhagen; AlessandroCeschi; Aoife MHarbison; DanielMair; PaoloFerrari; KatherineSmollett; FedericaSallusto; StephenCarmichael; ChristianGarzoni; JennaNichols; MassimoGalli; JosephHughes; AgostinoRiva; AntoniaHo; MarcoSchiuma; Malcolm GSemple; Peter JMOpenshaw; ElisaFadda; J KennethBaillie; John DChodera; ISARIC4C Investigators; COVID-19 Genomics UK (COG-UK) Consortium; Suzannah JRihn; Samantha JLycett; Herbert WVirgin; AmalioTelenti; DavideCorti; David LRobertson; GyorgySnell; ISARIC4C Investigators, COVID-19 Genomics UK (COG-UK) Consortium; (2021) Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell, 184 (5). 1171-1187.e20. ISSN 0092-8674 DOI: 10.1016/j.cell.2021.01.037
Copy

SARS-CoV-2 can mutate and evade immunity, with consequences for efficacy of emerging vaccines and antibody therapeutics. Here, we demonstrate that the immunodominant SARS-CoV-2 spike (S) receptor binding motif (RBM) is a highly variable region of S and provide epidemiological, clinical, and molecular characterization of a prevalent, sentinel RBM mutation, N439K. We demonstrate N439K S protein has enhanced binding affinity to the hACE2 receptor, and N439K viruses have similar in vitro replication fitness and cause infections with similar clinical outcomes as compared to wild type. We show the N439K mutation confers resistance against several neutralizing monoclonal antibodies, including one authorized for emergency use by the US Food and Drug Administration (FDA), and reduces the activity of some polyclonal sera from persons recovered from infection. Immune evasion mutations that maintain virulence and fitness such as N439K can emerge within SARS-CoV-2 S, highlighting the need for ongoing molecular surveillance to guide development and usage of vaccines and therapeutics.



picture_as_pdf
PIIS0092867421000805.pdf
subject
Published Version
Available under Creative Commons: 3.0

View Download

Explore Further

Read more research from the creator(s):

Find work associated with the faculties and division(s):

Find work associated with the research centre(s):

Find work from this publication: